Payment overview · 2025
General Payments
$23,772.19
120 reported records · 22 companies
Healthcare provider profile · identity verified
James Kyle Turnbo, M.D. PSC
Allopathic & Osteopathic Physicians|Family Medicine · PADUCAH, KY · NPI 1750483822
Verified facts
What the public records show
CMS Open Payments records show James Kyle Turnbo, M.D. PSC received $23,772.19 in general payments during 2025 across 120 reported records.
Amgen Inc. accounted for 94.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Rybelsus, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $22,446.32 | 94.4% | 40 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $212.62 | 0.9% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $170.11 | 0.7% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $166.18 | 0.7% | 10 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $111.78 | 0.5% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $111.27 | 0.5% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $81.22 | 0.3% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $69.15 | 0.3% | 4 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $52.15 | 0.2% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.67 | 0.2% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.38 | 0.2% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $35.75 | 0.1% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $34.55 | 0.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.74 | 0.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.89 | 0.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.38 | 0.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $25.82 | 0.1% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $18.39 | 0.1% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.72 | 0.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.51 | 0.1% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $15.59 | 0.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.00 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $20,800.00 | 11 |
| Food and Beverage | $1,873.47 | 100 |
| Travel and Lodging | $1,098.72 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $22,430.51 | 39 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $176.44 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $170.06 | 12 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $168.73 | 12 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $111.78 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $101.01 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $101.01 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $93.16 | 7 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $81.22 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $76.87 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $76.87 | 5 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $52.15 | 3 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $48.16 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.58 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $41.67 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $37.38 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $35.75 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $34.55 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $33.97 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $33.74 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.89 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.43 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $28.38 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $25.82 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| Extended Holter Normalized: extended holter |
Device | Philips North America LLC | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 178 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 149 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 162 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 165 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 52 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
48 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
121 | 36 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
48 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
186 | 35 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
149 | 38 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
178 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
149 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
162 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
165 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
178 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 770 | 195 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 661 | 190 |
| Atorvastatin Calcium | Atorvastatin Calcium | 654 | 171 |
| Metoprolol Succinate | Metoprolol Succinate | 546 | 145 |
| Losartan Potassium | Losartan Potassium | 532 | 164 |
| Pantoprazole Sodium | Pantoprazole Sodium | 472 | 131 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 435 | 78 |
| Gabapentin | Gabapentin | 432 | 102 |
| Alprazolam | Alprazolam | 423 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 421 | 123 |
| Omeprazole | Omeprazole | 329 | 97 |
| Tamsulosin Hcl | Tamsulosin Hcl | 328 | 95 |
| Lisinopril | Lisinopril | 297 | 93 |
| Metformin Hcl | Metformin Hcl | 255 | 71 |
| Tramadol Hcl | Tramadol Hcl | 236 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 223 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 216 | 65 |
| Duloxetine Hcl | Duloxetine Hcl | 215 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 213 | 54 |
| Clonazepam | Clonazepam | 207 | 33 |
| Pregabalin | Pregabalin | 203 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 203 | 46 |
| Meloxicam | Meloxicam | 198 | 51 |
| Fenofibrate | Fenofibrate Nanocrystallized | 196 | 50 |
| Furosemide | Furosemide | 196 | 63 |
| Farxiga | Dapagliflozin Propanediol | 186 | 35 |
| Montelukast Sodium | Montelukast Sodium | 180 | 44 |
| Eliquis | Apixaban | 178 | 42 |
| Carvedilol | Carvedilol | 167 | 45 |
| Fluoxetine Hcl | Fluoxetine Hcl | 166 | 46 |
| Bupropion Xl | Bupropion Hcl | 165 | 40 |
| Ozempic | Semaglutide | 165 | 29 |
| Mounjaro | Tirzepatide | 162 | 35 |
| Trazodone Hcl | Trazodone Hcl | 156 | 39 |
| Alendronate Sodium | Alendronate Sodium | 153 | 35 |
| Simvastatin | Simvastatin | 153 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 153 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 151 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 151 | 40 |
| Jardiance | Empagliflozin | 149 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 142 | 54 |
| Lorazepam | Lorazepam | 142 | 23 |
| Potassium Chloride | Potassium Chloride | 140 | 32 |
| Celecoxib | Celecoxib | 134 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 131 | 34 |
| Pioglitazone Hcl | Pioglitazone Hcl | 127 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 38 |
| Synthroid | Levothyroxine Sodium | 121 | 36 |
| Sertraline Hcl | Sertraline Hcl | 118 | 32 |
| Xarelto | Rivaroxaban | 118 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 117 | 25 |
| Allopurinol | Allopurinol | 113 | 33 |
| Famotidine | Famotidine | 112 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 28 |
| Spironolactone | Spironolactone | 103 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 103 | 19 |
| Donepezil Hcl | Donepezil Hcl | 101 | 17 |
| Ezetimibe | Ezetimibe | 100 | 30 |
| Fenofibrate | Fenofibrate | 97 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 97 | 20 |
| Temazepam | Temazepam | 95 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 94 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 92 | 27 |
| Buspirone Hcl | Buspirone Hcl | 91 | 25 |
| Metformin Hcl Er | Metformin Hcl | 91 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 89 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 89 | 22 |
| Bumetanide | Bumetanide | 88 | 31 |
| Diazepam | Diazepam | 86 | 28 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 79 | 25 |
| Ondansetron Odt | Ondansetron | 78 | 24 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 77 | 33 |
| Memantine Hcl | Memantine Hcl | 75 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 69 | 20 |
| Colestipol Hcl | Colestipol Hcl | 68 | 20 |
| Methylprednisolone | Methylprednisolone | 68 | 57 |
| Sucralfate | Sucralfate | 67 | 24 |
| Benazepril Hcl | Benazepril Hcl | 66 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 66 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 64 | 15 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 63 | 63 |
| Eszopiclone | Eszopiclone | 63 | 11 |
| Azithromycin | Azithromycin | 61 | 54 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 16 |
| Estradiol | Estradiol | 60 | 18 |
| Ramipril | Ramipril | 60 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 58 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 58 | 16 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 56 | 14 |
| Repatha Sureclick | Evolocumab | 56 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 53 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 52 | 29 |
| Rybelsus | Semaglutide | 52 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 50 | 16 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 50 | 47 |
| Topiramate | Topiramate | 50 | 16 |
| Azelastine Hcl | Azelastine Hcl | 48 | 22 |
| Linzess | Linaclotide | 48 | 18 |
| Myrbetriq | Mirabegron | 48 | 16 |
| Fluconazole | Fluconazole | 47 | 36 |
| Prednisone | Prednisone | 46 | 24 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 45 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 16 |
| Finasteride | Finasteride | 43 | 13 |
| Nifedipine Er | Nifedipine | 43 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 42 | 13 |
| Terbinafine Hcl | Terbinafine Hcl | 42 | 14 |
| Propranolol Hcl Er | Propranolol Hcl | 41 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 41 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 40 | suppressed |
| Irbesartan | Irbesartan | 39 | suppressed |
| Aripiprazole | Aripiprazole | 38 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | 12 |
| Sotalol | Sotalol Hcl | 38 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 38 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 31 |
| Glipizide Er | Glipizide | 37 | 12 |
| Modafinil | Modafinil | 37 | suppressed |
| Verapamil Er | Verapamil Hcl | 37 | suppressed |
| Lansoprazole | Lansoprazole | 36 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 36 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 35 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 33 |
| Clobetasol Propionate | Clobetasol Propionate | 34 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | 15 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 18 |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 14 |
| Praluent Pen | Alirocumab | 32 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Nystatin | Nystatin | 31 | 14 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 30 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 19 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Niacin Er | Niacin | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Digoxin | Digoxin | 26 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 25 | 11 |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | 15 |
| Klor-Con M20 | Potassium Chloride | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Metronidazole | Metronidazole | 24 | 16 |
| Atenolol | Atenolol | 23 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 23 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 23 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Multaq | Dronedarone Hcl | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Ranolazine Er | Ranolazine | 22 | suppressed |
| Triazolam | Triazolam | 22 | suppressed |
| Vraylar | Cariprazine Hcl | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 14 |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Cefdinir | Cefdinir | 20 | 16 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 13 |
| Repatha Syringe | Evolocumab | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Febuxostat | Febuxostat | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Lubiprostone | Lubiprostone | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 17 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Movantik | Naloxegol Oxalate | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Ubrelvy | Ubrogepant | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 12 |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Dexilant | Dexlansoprazole | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Humira(Cf) Pen | Adalimumab | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $23,772.19 · 120 records | Amgen Inc. | AIRSUPRA, Auvelity, Cologuard Collection Kit, Dexcom G6 Transmitter, Dyanavel XR, ELIQUIS, EVENITY, Extended Holter, GEMTESA, JARDIANCE, Jornay PM, Kerendia, LEQVIO, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, Omnipod, Ozempic, PROLIA, QULIPTA, REPATHA, Rybelsus, Symbravo, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, ZEPBOUND, ZORYVE | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error